July 14, 2025

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m...

The ASCO Post

July 11, 2025

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneou...

The ASCO Post

July 10, 2025

Team-Based Approach Tackles the Deadly Diagnosis of Glioblastoma

The multidisciplinary brain tumor team of Baptist Health Miami Cancer Institute and Baptist Health Miami Neuroscience Institute delivers advanced therapies tailored to each patient’s specific needs, balancing aggressive treatment with quality of life.

Baptist Health South Florida

July 10, 2025

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrat...

The ASCO Post

July 02, 2025

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity risk associated with lean bo...

The ASCO Post

July 01, 2025

Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens

As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (AR...

The ASCO Post

July 01, 2025

HER3-DXd in NSCLC Without EGFR-Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd...

The ASCO Post

July 01, 2025

Dana-Farber Research News 07.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.

Dana-Farber

June 30, 2025

Prostate Cancer Highlights from ASCO 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2025.

Dana-Farber